Stock vs Stock Comparison

Alnylam Pharmaceuticals, Inc. vs AbbVie Inc.

ALNY wins the Tale of the Tape 6–3.

ALNY$286.12
ABBV$215.40

🏆 Tale of the Tape

63
ALNYABBV
8.5%Profitability (Net Margin)6.9%
75.7xValuation (P/E)106.2x
13.0%Efficiency (ROIC)8.3%
6/9Health (Piotroski F)7/9
6.0Safety (Altman Z)2.0
65.2%Growth (Rev YoY)8.6%
0.87Risk (Sharpe 1Y)0.61
5.29xBalance Sheet (D/E)-42.50x
1.10%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.252
252-Day Correlation
0.182
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricALNYABBV
Market Cap$40.3B$384.7B
P/E Ratio75.7x106.2x
Forward P/E21.7x13.4x
P/B37.47x-57.80x
Dividend Yield3.18%
Beta0.300.30

Quantitative Metrics

MetricALNYABBV
DCF Fair Value$56.12$126.26
DCF Upside-83.2%-38.9%
Piotroski F6/97/9
Altman Z6.042.01
Beneish M-1.95-2.87
FCF Yield1.10%4.23%
Net Debt/EBITDA-1.0x3.0x
ROIC13.0%8.3%
WACC7.9%7.4%
ROIC – WACC5.1pp0.8pp
Gross Margin81.6%70.2%
Net Margin8.5%6.9%
Rev Growth YoY65.2%8.6%
Sharpe (1Y)0.870.61
Max Drawdown 3Y-37.6%
FCF Payout Ratio65%

ALNY Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

ALNY found in:

IBB3.77%
XBI1.09%
VOT0.97%
VHT0.66%
VXF0.50%
VO0.42%
VFMO0.19%
VONG0.13%
VUG0.13%
QUS0.09%
ESGV0.08%
VTI0.06%
VONE0.06%
VT0.04%
ONEO0.01%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ALNY vs ABBV: Head-to-Head Analysis

Alnylam Pharmaceuticals, Inc. (ALNY) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ALNY leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ALNY generates a return on invested capital (ROIC) of 13.0% compared to ABBV's 8.3%. This suggests ALNY is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ALNY and ABBV is 0.252, indicating low correlation, making them an effective diversification pair in a portfolio context.

ALNY appears in 15 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ALNY or ABBV?

Our quantitative analysis compares ALNY and ABBV across nine fundamental dimensions. ALNY wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ALNY and ABBV correlated?

The 252-day correlation between ALNY and ABBV is 0.252. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.